Share chart Madrigal Pharmaceuticals, Inc.
Extended chart
Simple chart
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., биофармацевтическая компания на клинической стадии, специализируется на разработке и коммерциализации терапевтических кандидатов для лечения сердечно-сосудистых, метаболических заболеваний и заболеваний печени. Его ведущим кандидатом в продукт является MGL-3196, избирательный агонист рецептора тироидных гормонов, направленный на печень, который проходит III фазу клинических испытаний для лечения неалкогольного стеатогепатита. Компания заключила соглашение с Hoffmann-La Roche об исследованиях, разработках и коммерциализации. more details| IPO date | 2007-02-06 |
|---|---|
| ISIN | US5588681057 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.madrigalpharma.com |
| Цена ао | 303.64 |
| Change price per day: | -3.53% (340.14) |
|---|---|
| Change price per week: | +11.75% (293.64) |
| Change price per month: | +5.17% (312) |
| Change price per 3 month: | +55.76% (210.67) |
| Change price per half year: | +17.2% (279.99) |
| Change price per year: | +45.21% (225.97) |
| Change price per 3 year: | +396.35% (66.11) |
| Change price per 5 year: | +295.11% (83.05) |
| Change price per 10 year: | 0% (328.14) |
| Change price per year to date: | -0.0152% (328.19) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 17.01.2025 | 17.01.2025 | Taub Rebecca Pres., R&D, and CMO |
Sale | 273.41 | 461 789 | 1689 | 0 | -0.01 | link |
| 17.01.2025 | 17.01.2025 | Waltermire Robert E. Senior VP, Chief Pharma Dev. |
Sale | 273.41 | 120 847 | 442 | 0 | 0 | link |
| 17.01.2025 | 17.01.2025 | Kelley Shannon T General Counsel |
Sale | 273.41 | 75 735 | 277 | 0 | 0 | link |
| 09.09.2024 | 11.09.2024 | Sibold William John President and CEO |
Sale | 243.83 | 1 551 490 | 6363 | 0 | -0.04 | link |
| 09.09.2024 | 10.09.2024 | William John Sibold Officer |
Purchase | 243.83 | 1 551 490 | 6363 | 0 | 0.04 | link |
| 14.06.2024 | 18.06.2024 | Waltermire Robert E. Senior VP, Chief Pharma Dev. |
Sale | 280 | 532 000 | 1900 | 0 | -0.01 | link |
| 14.06.2024 | 18.06.2024 | Waltermire Robert E. Senior VP, Chief Pharma Dev. |
Purchase | 87.09 | 165 471 | 1900 | 0 | 0.01 | link |
| 12.06.2024 | 14.06.2024 | Waltermire Robert E. Senior VP, Chief Pharma Dev. |
Sale | 285 | 570 000 | 2000 | 0 | -0.01 | link |
| 12.06.2024 | 14.06.2024 | Waltermire Robert E. Senior VP, Chief Pharma Dev. |
Purchase | 87.92 | 175 840 | 2000 | 0 | 0.01 | link |
| 21.05.2024 | 23.05.2024 | Waltermire Robert E. Senior VP, Chief Pharma Dev. |
Sale | 231.34 | 239 668 | 1036 | 0 | -0.01 | link |
| 14.05.2024 | 16.05.2024 | CRAVES FRED B Director |
Sale | 212.88 | 4 787 460 | 22489 | 0 | -0.13 | link |
| 14.05.2024 | 16.05.2024 | CRAVES FRED B Director |
Purchase | 103.02 | 2 316 820 | 22489 | 0 | 0.13 | link |
| 08.04.2024 | 10.04.2024 | FRIEDMAN PAUL A Director |
Sale | 246.19 | 6 467 410 | 26270 | 0 | -0.15 | link |
| 08.04.2024 | 10.04.2024 | FRIEDMAN PAUL A Director |
Purchase | 9.45 | 248 252 | 26270 | 0 | 0.15 | link |
| 08.04.2024 | 10.04.2024 | Taub Rebecca Pres., R&D, and CMO |
Sale | 245.99 | 658 269 | 2676 | 0 | -0.02 | link |
| 08.04.2024 | 10.04.2024 | Taub Rebecca Pres., R&D, and CMO |
Purchase | 9.45 | 25 288 | 2676 | 0 | 0.02 | link |
| 05.04.2024 | 05.04.2024 | FRIEDMAN PAUL A Director |
Sale | 243.4 | 6 721 000 | 27613 | 0 | -0.16 | link |
| 05.04.2024 | 05.04.2024 | FRIEDMAN PAUL A Director |
Purchase | 9.45 | 260 943 | 27613 | 0 | 0.16 | link |
| 04.04.2024 | 05.04.2024 | FRIEDMAN PAUL A Director |
Sale | 242.96 | 4 545 780 | 18710 | 0 | -0.11 | link |
| 04.04.2024 | 05.04.2024 | FRIEDMAN PAUL A Director |
Purchase | 9.45 | 176 810 | 18710 | 0 | 0.11 | link |
| 03.04.2024 | 05.04.2024 | FRIEDMAN PAUL A Director |
Sale | 245.12 | 6 718 000 | 27407 | 0 | -0.16 | link |
| 03.04.2024 | 05.04.2024 | FRIEDMAN PAUL A Director |
Purchase | 9.45 | 258 996 | 27407 | 0 | 0.16 | link |
| 14.12.2023 | 14.12.2023 | BAKER BROS. ADVISORS LP Director |
Purchase | 228.32 | 4 710 930 | 20633 | 0 | 0.12 | link |
| 13.12.2023 | 14.12.2023 | BAKER BROS. ADVISORS LP Director |
Purchase | 219.39 | 17 805 500 | 81159 | 0 | 0.47 | link |
| 12.12.2023 | 14.12.2023 | BAKER BROS. ADVISORS LP Director |
Purchase | 218.31 | 7 548 720 | 34578 | 0 | 0.2 | link |
| Institutions | Volume | Share, % |
|---|---|---|
| Price (T.Rowe) Associates Inc | 803 | 3.77 |
| FMR, LLC | 714 | 3.35 |
| State Street Corporation | 625 | 2.93 |
| Perceptive Advisors LLC | 430 | 2.02 |
| Janus Henderson Group PLC | 3 | 12.21 |
| Baker Brothers Advisors, LLC | 2 | 9.24 |
| Avoro Capital Advisors LLC | 2 | 9.12 |
| Paulson & Company, Inc. | 2 | 8.33 |
| Vanguard Group Inc | 2 | 7.83 |
| Blackrock Inc. | 1 | 5.68 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research & Development and Director | 939.83k | 1952 (73 years) |
| Mr. Edward Chiang | Senior Vice President of Clinical & Technical Operations | N/A | |
| Mr. William J. Sibold | CEO, President & Director | N/A | 1966 (59 years) |
| Mr. Ronald Filippo | Chief Information Officer | N/A | |
| Ms. Mardi C. Dier | CFO & Senior VP | N/A | 1964 (61 year) |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | N/A | |
| Mr. Clint Wallace | Chief Human Resources Officer | N/A | |
| Ms. Carole Huntsman | Chief Commercial Officer | 1965 (60 years) | |
| Ms. Shannon Kelley | Chief Compliance Office & General Counsel | ||
| Mr. Thomas W. Hare | Senior Vice President of Clinical Management |
Address: United States, West Conshohocken, PA , Four Tower Bridge - open in Google maps, open in Yandex maps
Website: https://www.madrigalpharma.com
Website: https://www.madrigalpharma.com
